Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Matheson, E. C.
Right arrow Articles by Hall, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matheson, E. C.
Right arrow Articles by Hall, A. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 24, No. 1, 31-38, January 2003
© 2003 Oxford University Press

CANCER BIOLOGY

Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia

Elizabeth C. Matheson and Andrew G. Hall1

The LRF Molecular Pharmacology Specialist Programme, Cancer Research Unit, Newcastle upon Tyne, UK

Defects in the DNA mismatch repair (MMR) pathway have recently been shown to be associated with resistance to several of the cytotoxic drugs used in the treatment of children with acute lymphoblastic leukaemia (ALL). We have assessed the MMR status of a range of leukaemic cell lines using an in vitro repair assay and correlated this with protein expression of the best characterized components of the system. We have also assessed MMR in leukaemic blasts from a limited panel of children with ALL and related this to Ki67 expression as a measure of proliferative capacity. Out of nine leukaemic cell lines tested, five of the seven lymphoid lines showed little or no repair using the in vitro assay and had low MMR protein expression. In three (NALM-6, Reh and MOLT 4) MMR defects have not been previously reported. Immunohistochemistry of clinical samples showed a wide range of expression of MLH1, MSH2 and Ki67 in nine cases studied at presentation, with a highly statistically significant correlation between MLH1 and Ki67 expression (r2 = 0.96, P < 0.0001, Pearson correlation). Western blotting demonstrated high expression of MLH1, PMS2, MSH2 and MSH6 proteins. In vitro analysis of G.T repair using lymphoblast cytosol from the same patients showed a wide range of proficiency, which was markedly reduced in one case studied at relapse. These results suggest that MMR defects are more common in leukaemic cell lines and acute lymphoblastic leukaemias than previously thought.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
J. J. Yang, D. Bhojwani, W. Yang, X. Cai, G. Stocco, K. Crews, J. Wang, D. Morrison, M. Devidas, S. P. Hunger, et al.
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
Blood, November 15, 2008; 112(10): 4178 - 4183.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Yamauchi, M. Ogawa, and T. Ueda
Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance
Mol. Pharmacol., July 1, 2008; 74(1): 82 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Stoklosa, T. Poplawski, M. Koptyra, M. Nieborowska-Skorska, G. Basak, A. Slupianek, M. Rayevskaya, I. Seferynska, L. Herrera, J. Blasiak, et al.
BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point Mutations
Cancer Res., April 15, 2008; 68(8): 2576 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. C. Matheson, L. A. Hogarth, M. C. Case, J. A.E. Irving, and A. G. Hall
DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo
Carcinogenesis, June 1, 2007; 28(6): 1341 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
P. Karran
Thiopurines, DNA damage, DNA repair and therapy-related cancer
Br. Med. Bull., February 2, 2007; (2007) ldl020v1.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. Schmidt, J. A. E. Irving, L. Minto, E. Matheson, L. Nicholson, A. Ploner, W. Parson, A. Kofler, M. Amort, M. Erdel, et al.
Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor
FASEB J, December 1, 2006; 20(14): 2600 - 2602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A.E. Irving, L. Minto, S. Bailey, and A. G. Hall
Loss of Heterozygosity and Somatic Mutations of the Glucocorticoid Receptor Gene Are Rarely Found at Relapse in Pediatric Acute Lymphoblastic Leukemia but May Occur in a Subpopulation Early in the Disease Course
Cancer Res., November 1, 2005; 65(21): 9712 - 9718.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. R. Velangi, E. C. Matheson, G. J. Morgan, G. H. Jackson, P. R. Taylor, A. G. Hall, and J. A.E. Irving
DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma
Carcinogenesis, October 1, 2004; 25(10): 1795 - 1803.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.